Get the Stockscreener App
3.50
12.50%
-0.50
After Hours:
3.49
-0.010
-0.29%
Traws Pharma Inc stock is traded at $3.50, with a volume of 90,989.
It is down -12.50% in the last 24 hours and down -47.99% over the past month.
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
See More
Previous Close:
$4.00
Open:
$4
24h Volume:
90,989
Relative Volume:
0.17
Market Cap:
$12.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-30.83%
1M Performance:
-47.99%
6M Performance:
-62.16%
1Y Performance:
+0.00%
1-Day Range:
$3.33
$4.20
1-Week Range:
$3.33
$5.26
52-Week Range:
$3.33
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
3.50 | 12.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
TRAW stock touches 52-week low at $4.06 amid market challenges - Investing.com UK
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MSN
Traws Pharma amends Series A Warrant terms - Investing.com
Traws Pharma amends Series A Warrant terms By Investing.com - Investing.com UK
Traws Pharma secures stockholder nod for warrant issuance By Investing.com - Investing.com Nigeria
Traws Pharma secures stockholder nod for warrant issuance - Investing.com India
Traws Pharma, Expert Systems: Breakthrough in H5N1Bird Flu antiviral program - MSN
Onconova Therapeutics Announces Completion of Enrollment of Phase 3 Inspire Trial -March 24, 2020 at 04:05 pm EDT - Marketscreener.com
Traws Pharma completes Phase I trials of H5N1 bird flu treatment drug - MSN
Traws Pharma Names Nora Brennan Interim CFO -February 07, 2025 at 04:43 pm EST - Marketscreener.com
Traws Pharma Inc. Announces CFO Changes -February 07, 2025 at 04:31 pm EST - Marketscreener.com
Orbimed Advisors LLC Expands Stake in Traws Pharma Inc - GuruFocus.com
Traws Pharma Advances Bird Flu Treatment with Successful Phase I Trial - MSN
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - Marketscreener.com
Traws Pharma's Bird Flu Drug Shows Promise in Phase I Safety Trial, Targets H5N1 Prevention - StockTitan
Traws Pharma Shares Surge 57% in After-Hours Trading Following Antiviral Trial Update - Yahoo Finance
Traws Pharma (TRAW) Stock Skyrockets In After-Hour Trading - Stocks Telegraph
Traws Pharma Shares Surge 57% in After-Hours Trading Following A - GuruFocus.com
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program - The Malaysian Reserve
Traws stock rallies 24% on avian flu drug update - MSN
Expert Systems And Traws Pharma Report Breakthrough In H5n1bird Flu Antiviral Program - MENAFN.COM
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Traws Phar - GuruFocus.com
Traws Pharma Secures $72.6 Million for Bird Flu Treatment Development - MSN
SEC Form 424B4 filed by Traws Pharma Inc. - Quantisnow
Traws Pharma secures up to $72.6 million in funding By Investing.com - Investing.com Canada
Traws stock plunges 43% on financing update - MSN
Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding - Marketscreener.com
Is Traws Pharma Inc (NASDAQ: TRAW) Doomed From The Get-Go? - Stocks Register
Bucks County firm's shares plunge on capital raise plan - The Business Journals
Traws stock plunges 43% on financing update (TRAW:NASDAQ) - Seeking Alpha
Crude Oil Gains 1%; Chicago PMI Falls In December - Benzinga
Stock market news: Abpro Holdings -52.75%, Traws Pharma -42.47% among biggest losers during mid day trading - Business Upturn
Dismal Market Sentiment Pushes VIX Higher - Schaeffers Research
Traws Pharma Secures $72.6 Million in Financing to Advance Bird Flu Treatment Development - Tandav Media
Stock market today: Abpro Holdings -42.09%, Traws Pharma -39.26% among biggest losers in early trading - Business Upturn
Stock market news: Intrusion surged by 123.33% while Snow Lake Resources plunged by 21.88% in early trading - Business Upturn
Traws Pharma secures up to $72.6 million in funding - Investing.com India
Traws Pharma announces $72.6M financing - TipRanks
Traws Pharma Secures $72.6M Financing for Bird Flu Drug Development from Leading Healthcare Investors - StockTitan
Single Peoples' Personalities Differ from Partnered Peoples' - 69News WFMZ-TV
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval - Finansavisen
Traws Pharma stock soars 200% on encouraging bird flu drug data - MSN
Traws Pharma soars as it advances H5N1 bird flu treatment - The Pharma Letter
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu - Marketscreener.com
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November - Benzinga
Traws Pharma (TRAW) Shares Jump On Strong Trial Results - Stocks Telegraph
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results - Benzinga
Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars - MSN
Stock market news: Direct Digital Holdings +405.45%, Reliance Global Group +214.17% among top gainers during mid day trading - Business Upturn
Stock market news: Direct Digital Holdings up by 363.64% while iLearningEngines down by 70.88% during mid day trading - Business Upturn
Traws Pharma Inc Stock (TRAW) Financials Data
There is no financial data for Traws Pharma Inc (TRAW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):